Participants
pain, CRPS, Pain
COMPLEX REGIONAL PAIN SYNDROME
In total, 24 participants were randomized and received treatment during part A (soticlestat, n = 15; placebo, n = 9) (Baseline demographics were generally balanced between the soticlestat and placebo groups (Baseline demographics and clinical characteristics (safety analysis set)CRPS = complex regional pain syndrome; CSS = CRPS Severity Score; NPS = Numeric Pain Scale; PROMIS = Patient-Reported Outcomes Measurement Information System; SD = standard deviation.n = 5.n = 6.n = 7.n = 8.The median duration of treatment during part A was 103 days (range, 14–111 days) in the soticlestat group and 105 days (range, 7–108 days) in the placebo group. The median duration of treatment with soticlestat during part B was 98 days (range, 6–109 days).During screening, all participants had an E-diary response rate of more than 90% for pain intensity scores. During treatment, only one participant out of 24 had a response rate of less than 90% (88.9%).